Immunotherapy with checkpoint blockade induces rapid and durable immune control of
cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen …

Abstract B7-H3 (CD276), a member of the B7 family of proteins, is a key player in cancer
progression. This immune checkpoint molecule is selectively expressed in both tumor cells …

The human immune system is composed of a distributed network of cells circulating
throughout the body, which must dynamically form physical associations and communicate …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Universal CAR T-cell therapies are poised to revolutionize cancer treatment and to improve
patient outcomes. However, realizing these advantages in an allogeneic setting requires …

New approaches beyond PD-1/PD-L1 inhibition are required to target the immunologically
diverse tumor microenvironment (TME) in high-grade serous ovarian cancer (HGSOC). In …

Different immunotherapeutic approaches have proved to be of significant clinical value to
many patients with different types of advanced cancer. However, we need more precise …

Objective Aberrant expression of the immune checkpoint molecule, CD276, also known as
B7-H3, is associated with tumorigenesis. In this review, we aim to comprehensively describe …

Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges.
KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has …

Abstract CD155 (PVR/necl5/Tage4), a member of the nectin-like family of adhesion
molecules, is highly upregulated on tumor cells across multiple cancer types and has been …